Clinical Trials · NCT02914158
Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women
- Phase
- Phase 3
- Recruitment status
- Unknown
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
- Enrollment
- 680
- Start date
- Mar 2016
- Locations
- 25 sites, China
- Primary endpoint
- Disease-Free Survival (DFS)